DENVER—Adolescents and young adults with inflammatory bowel disease can switch from the originator to a biosimilar of infliximab with no loss of response or increased side effects, according to research presented at the 2023 Crohn’s & Colitis Congress.
The retrospective analysis of 53 patients found no significant effect on clinical remission rates, laboratory markers of inflammation, serious adverse events, anti–tumor necrosis factor-alpha inhibitor (anti-TNF) levels, or